NICE seeks positive future with life sciences industry

NICE has set out its position on its complex but positive relationship with the life sciences industry.

Most of NICE’s work has an impact on the industry.

At NICE’s January Board meeting, the Board agreed a position statement setting out in detail the important relationship NICE has with the life sciences industry.

Sir Andrew Dillon, chief executive of NICE, said: “As the independent body issuing guidance to the NHS, NICE has a complex relationship with the life sciences industry.

“This is a good moment for us to reflect on our relationship with the industry and to set out what we can do contribute to its long term prospects, whilst maintaining our focus on primary role in helping patients and the NHS get the best outcomes from the resources available. This position paper sets out how we can do that.”

“We want it to provide the basis for our engagement with the Government’s emerging life sciences strategy, as an agenda for our work with the industry, and as a public statement of our role and our commitment to supporting the growth of a thriving life sciences sector.”

NICE continues to work with the industry and Government to develop innovative approaches to evaluate new technologies such as the Early Access to Medicines Scheme and the reformed Cancer Drugs Fund. And NICE’s dedicated Scientific Advice programme and Office of Market Access have also created new opportunities to engage with the industry.